Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen

American Journal of Cardiology

Volumn 79, Issue 11, 1997, Pages 1471-1474

  Ochiai, Masahiko ^a   Isshiki, Takaaki ^a   Takeshita, Satoshi ^a   Eto, Koji ^a   Toyoizumi, Hideki ^a   Sato, Tomohide ^a   Miyashita, Hideo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STENT; THROMBOSIS;

ADULT; AGED; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; STENTS; TETRAZOLES; TREATMENT OUTCOME;

EID: 0030978007     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00173-2     Document Type: Article

References (20)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Deter K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Manterne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel MA. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
3. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound. Circulation. 91:1995;1676-1688.
4. Morice MC, Zemour G, Benveniste E, Biron Y, Bourdonnec C, Faivre R, Fajadet J, Gaspard P, Glatt B, Joly P, Labrunie P, Lienhart Y, Marco J, Petiteau PY, Royer T, Valeix B. Intracoronary stenting without coumadin: one-month results of a French multicenter study. Cathet Cardiovasc Diagn. 35:1995;1-7.
5. Morice MC. Advances in post stenting medication protocol. J Invas Cardiol. 7:1995;32A-35A.
6. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Righardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 334:1996;1084-1089.
7. Goods CM, Al-Shaibi KF, Negus BH, Liu MW, Yadav SS, Jain SP, Dean LS, Iyer SS, Parks JM, Roubin GS. Is ticlopidine a necessary component of antiplatelet regimens following coronary artery stenting (abstr). J Am Coll Cardiol. 27:((suppl A)):1996;137A.
8. Nishi T, Tabusa F, Tanaka T, Shimizu T, Nakagawa K. Studies on 2-oxoquinolinone derivatives as blood platelet aggregation inhibitors IV. Synthesis and biological activity of metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl) butoxyl]-2-oxo-1, 2, 3, 4-tetrahydroquinolinone (OPC - 13013). Chem Pharm Bull (Tokyo). 33:1985;1140-1147.
9. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung Drug Res. 35:1985;1144-1149.
10. Ikeda Y, Kikuchi M, Murakami H. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo: randomized, double-blind cross-over study. Arzneimittelforschung Drug Res. 37:1987;563-566.
11. Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardiovasc Drug Rev. 11:1993;451-465.
12. Mishima Y, Tanabe T, Sakaguchi S, Katsumura T, Kusaba A, Uchida H. Clinical evaluation of OPC-13013 on chronic arterial occlusive disease - a double-blind study with ticlopidine. Igaku no Ayumi. 139:1986;133-157.
13. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB Jr III, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL Jr. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation. 78:1988;486-502.
14. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med. 321:1989;501-507.
15. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 93:1996;215-222.
16. Hardisty RM, Powling MJ, Nokes TJC. The action of ticlopidine on human platelets: studies on aggregation, secretion, calcium mobilization, and membrane glycoproteins. Thromb Haemost. 64:1990;105-155.
17. Vermylen J, Verstraete M, Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol. 8:((suppl B)):1986;2B-9B.
18. Yasuda K, Tanabe T, Hashimoto M, Suzuki S, Shimizu T, Hosokawa Y. Effect of cilostazol a new antithrombotic drug, on small arterial replacement. Thromb Haemost. 35:1985;1189-1192.
19. Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishimine K, Makutani S, Sakaguchi S, Yoshikawa T, Ohishi H, Kimura Y, Yoshikawa T. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol. 30:1995;532-537.
20. Moussa I, Mario CD, Francesco LD, Reimers B, Blengino S, Colombo A2. Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Am J Cardiol. 78:((suppl 3A)):1996;13-17.